Overview

• White House officials say the threatened 100% import tax on certain brand‑name drugs will not take effect now, with the plan still under review as negotiations continue.
• Pfizer’s agreement with the administration includes most‑favored‑nation pricing access for state Medicaid programs, guarantees on newly launched drugs, a three‑year tariff reprieve and a reported $70 billion U.S. investment.
• Trump announced TrumpRx.gov, a federal direct‑to‑consumer site to sell select medicines at government‑negotiated discounts averaging about 50%, with launch targeted for early 2026 and initial participation from Pfizer.
• Industry voices, including Mark Cuban and other experts, say transparent cash prices could pressure PBMs and specialty pharmacy contracts, though the impact depends on how many manufacturers join and how many patients use the platform.
• Privacy and access concerns surfaced immediately, with legal experts warning about unclear data safeguards and independent pharmacists cautioning that tariff threats and price shifts could disrupt access to some brand‑name therapies.